CD9 expression is correlated with poor prognosis of gastric cancer whereas the expression in melanomas, myelomas, and head and neck squamous carcinomas is associated with early stages of cancer progression and positive treatment outcome [89, 90]. This evidence concerns the gene CD9 and gastric cancer.